UNSPSC 41171612: Oxidase screening test for gonorrhea

In this classification, a Oxidase screening test for gonorrhea connotes an in vitro device that consists of the articles intended to identify by chemical reaction, cytochrome oxidase, an oxidizing enzyme that is associated with certain bacteria including Neisseria gonorrhoeae. Because it is unlikely that cytochrome oxidase-positive organisms other than Neisseria gonorrhoeae are present in the urethral discharge of males, the identification of cytochrome oxidase with this device indicates presumptive infection of the patient with the causative agent of gonorrhea.

US FDA regulates Oxidase screening test for gonorrhea under 21 CFR 866.2420 and under FDA product code LGA.

UNSPSC 41171612 Oxidase screening test for gonorrhea is a Commodity code covering diagnostic laboratory tests for the detection of Neisseria gonorrhoeae, commonly used as part of STI screening and confirmation workflows in clinical and public health settings. State and local governments procure these tests primarily through health departments, county health offices, and clinical laboratory services that support STI prevention and treatment programs; purchasing typically flows through standing contracts, cooperative purchasing vehicles, or competitive RFQs for annual or multi-year supply agreements rather than project-specific solicitations.

The most-recent-state-local-contract-opportunities block contains no records for this code, indicating no active posted opportunities at this time. Without recent solicitation data, geographic concentration and issuing-body composition cannot be characterized from current market signals. Firms evaluating pursuit should monitor state health department procurement channels and regional cooperative purchasing consortia (such as state health purchasing cooperatives or regional laboratory supply agreements) for demand signals, as this code typically surfaces in routine supply renewals rather than formal competitive notices.